Wang H, Chen X, Chen Y, Cao Y, Chen Y, Liu G, Huang L
The first clinical college of Southern Medical University, Guangzhou 510515, China.
Southern Medical University of Nanfang Hospital, Obstetrics and Gynecology Department, Guangzhou 510515, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2021 Apr 20;41(4):555-561. doi: 10.12122/j.issn.1673-4254.2021.04.11.
To investigate the expression of ENTPD5 in epithelial ovarian cancer and explore its clinical implications.
The expression level of ENTPD5 in epithelial ovarian cancer was analyzed based on data from Oncomine and TCGA databases. The relationship between the expression level of ENTPD5 and clinical characteristics of the patients was analyzed using UALCAN database. Gene enrichment analysis (GSEA) was performed to explore the possible role of ENTPD5 in the occurrence and progression of epithelial ovarian cancer. CIBERSORT package was used to analyze the relationship between the expression of ENTPD5 and immune infiltration. The expression patterns of ENTPD5 were verified in 23 epithelial ovarian cancer tissues and 15 normal ovarian tissues using RT-qPCR and Western blotting; the expression of ENTPD5 protein was also detected immunohistochemically in 50 paraffin-embedded samples of epithelial ovarian cancer and 6 normal ovarian tissues.
Analysis of Oncomine and TCGA databases showed that the expression of ENTPD5 was significantly higher in epithelial ovarian cancer tissues than in normal ovarian tissues ( < 0.05), and its expression level was negatively correlated with the survival rate of the patients ( < 0.05). Data from UALCAN database showed that the expression level of ENTPD5 was related with the age of patients. The results of GSEA suggested that ENTPD5 was involved in ABC transporter, WNT signaling pathway and insulin signaling, and the expression of ENTPD5 was negatively correlated with the contents of NK cells, mast cells and eosinophils ( < 0.05). In clinical samples of epithelial ovarian cancer tissues, the expression of ENTPD5 was significantly higher than that in normal ovarian tissues at both the mRNA ( < 0.01) and protein ( < 0.05) levels. The paraffinembedded samples also showed significantly higher expressions of ENTPD5 in epithelial ovarian cancer than in normal ovarian tissues ( < 0.05).
ENTPD5 is highly expressed in epithelial ovarian cancer, which may promote the occurrence and progression of epithelial ovarian cancer by participating in multiple functional processes and cellular immune infiltration.
研究ENTPD5在上皮性卵巢癌中的表达情况，并探讨其临床意义。
基于Oncomine和TCGA数据库的数据，分析ENTPD5在上皮性卵巢癌中的表达水平。使用UALCAN数据库分析ENTPD5表达水平与患者临床特征之间的关系。进行基因富集分析（GSEA）以探讨ENTPD5在上皮性卵巢癌发生和发展中的可能作用。使用CIBERSORT软件包分析ENTPD5表达与免疫浸润之间的关系。采用RT-qPCR和Western印迹法在23例上皮性卵巢癌组织和15例正常卵巢组织中验证ENTPD5的表达模式；还采用免疫组织化学方法在50例上皮性卵巢癌石蜡包埋样本和6例正常卵巢组织中检测ENTPD5蛋白的表达。
Oncomine和TCGA数据库分析显示，ENTPD5在上皮性卵巢癌组织中的表达明显高于正常卵巢组织（<0.05），其表达水平与患者生存率呈负相关（<0.05）。UALCAN数据库的数据显示，ENTPD5的表达水平与患者年龄有关。GSEA结果表明，ENTPD5参与ABC转运蛋白、WNT信号通路和胰岛素信号通路，且ENTPD5的表达与自然杀伤细胞、肥大细胞和嗜酸性粒细胞的含量呈负相关（<0.05）。在上皮性卵巢癌组织的临床样本中，ENTPD5在mRNA（<0.01）和蛋白质（<0.05）水平上的表达均明显高于正常卵巢组织。石蜡包埋样本也显示，上皮性卵巢癌中ENTPD5的表达明显高于正常卵巢组织（<0.05）。
ENTPD5在上皮性卵巢癌中高表达，可能通过参与多种功能过程和细胞免疫浸润促进上皮性卵巢癌的发生和发展。
